Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carica papaya leaf extract is a **plant-derived botanical extract** prepared from the leaves of *Carica papaya* and has been studied as an oral supportive therapy for **dengue fever**, particularly to mitigate thrombocytopenia and possibly reduce progression to severe disease. In the provided public clinical-trial context, it is administered orally at 1000 mg three times daily for 5 days in placebo-controlled randomized studies of hospitalized or non-severe dengue patients. Its mechanism is **not definitively established** as a single-target pharmaceutical mechanism; reported and hypothesized effects in the literature include **platelet count support, immunomodulatory, antioxidant, and possible membrane-stabilizing or hematopoietic effects**, but it should be treated as a **multicomponent botanical extract rather than a precisely target-defined small-molecule drug**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carica papaya leaf extract.